Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
Hypoxia is a hallmark of many solid tumors and is associated with resistance to anticancer treatments. Hypoxia-activated prodrugs (HAPs) were developed to target the hypoxic regions of these tumors. Among 2nd generation HAPs, Evofosfamide (Evo, also known as TH-302) exhibits preclinical and clinical...
Main Authors: | Quentin Bailleul, Pauline Navarin, Mélanie Arcicasa, Christine Bal-Mahieu, Angel Montero Carcaboso, Xuefen Le Bourhis, Alessandro Furlan, Samuel Meignan, Pierre Leblond |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/8/1804 |
Similar Items
-
18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
by: Milan Grkovski, et al.
Published: (2018-06-01) -
Brainstem Glioma in Adults
by: Jethro Hu, et al.
Published: (2016-08-01) -
Diffuse intrinsic pontine glioma: Poised for progress
by: Katherine eWarren
Published: (2012-12-01) -
Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)
by: Cavan P. Bailey, et al.
Published: (2018-10-01) -
The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation
by: David Roig-Carles, et al.
Published: (2021-08-01)